Biodesix reports FY2021 revenue $54.5M; core lung diagnostic up 49% YoY to $18.7M; net loss $43.2M

BIODESIX INC

Q4 total revenue $7.2M; core lung diagnostic revenue $5.4M (+48% YoY); BioPharma services $1.4M (-29% YoY).
FY2021 total revenue $54.5M; core lung diagnostic $18.7M (+49% YoY); COVID-19 testing revenue $30.2M (+7% YoY).
Q4 gross margin 65% vs 46% YoY driven by mix shift to higher-margin lung diagnostics; operating expenses $16.4M.
Net loss Q4 $13.3M (increase of 193% YoY); FY2021 net loss $43.2M (increase 38% YoY).
Guides FY2022 total revenue $37.5M-$39.5M; cash $32.7M after $20M debt prepayment and $15.7M equity raise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.